论文部分内容阅读
目的探讨国产瑞格列奈联合甘精胰岛素治疗老年2型糖尿病的临床疗效。方法选取本院2010年2月至2012年9月收入院的2型糖尿病老年患者80例为研究对象,随机分为观察组(40例)和对照组(40例)。对照组给予预混胰岛素(诺和灵30R)治疗,观察组给予国产瑞格列奈联合甘精胰岛素治疗。治疗14 d后观察对比两组空腹血糖(FPG)、餐后2 h血糖(2 hPG)、HbA1c值的变化情况,低血糖的发生率、血糖达标所用的时间及日用胰岛素量。结果治疗后观察组FPG、2 hPG、HbA1c均恢复到正常水平,而对照组虽有所改善,但仍较正常值稍高,两组对比差异有统计学意义(P<0.05)。观察组血糖达标所用的时间也明显短于对照组(P<0.05);日用胰岛素量观察组明显少于对照组(P<0.05),观察组低血糖的发生率为5.0%,明显低于对照组的15.0%(P<0.05)。结论国产瑞格列奈联合甘精胰岛素可显著改善老年2型糖尿病患者的血糖水平,缩短治疗时间,降低日用胰岛素量,而且能够降低低血糖的发生率,值得临床推广。
Objective To investigate the clinical efficacy of domestic repaglinide combined with insulin glargine in the treatment of type 2 diabetes in the elderly. Methods Eighty elderly patients with type 2 diabetes mellitus admitted to our hospital from February 2010 to September 2012 were selected as study object and randomly divided into observation group (40 cases) and control group (40 cases). Control group was given premixed insulin (Novolin 30R) treatment, the observation group was given domestic repaglinide combined with insulin glargine. After 14 days of treatment, fasting blood glucose (FPG), postprandial 2-h blood glucose (2 hPG) and changes of HbA1c were observed and compared. The incidence of hypoglycemia, the time of reaching blood glucose level and daily insulin amount were observed and compared. Results After treatment, the levels of FPG, 2 hPG and HbA1c in the observation group returned to normal levels, while the control group improved, but still slightly higher than the normal value. The difference between the two groups was statistically significant (P <0.05). The time taken by the observation group to reach the blood glucose level was significantly shorter than that of the control group (P <0.05). The observed daily insulin level in the observed group was significantly less than that in the control group (P <0.05). The incidence of hypoglycemia in the observation group was 5.0% Control group, 15.0% (P <0.05). Conclusion Domestic repaglinide combined with insulin glargine can significantly improve the blood sugar level in elderly patients with type 2 diabetes, shorten the treatment time, reduce the daily amount of insulin, and can reduce the incidence of hypoglycemia, worthy of clinical promotion.